OptimizeRx Corp — Director's Dealing 2024

Feb 7, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2024-02-02

Reporting Person: KLEMA CATHY (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-02	Restricted Stock Units	$	A	5109	Acquired		Common Stock (5109)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.

F2: The restricted stock units will vest in full on the first anniversary of the date of grant.